AHA Scientific Sessions 2026 Abstract · Nov 2, 2026
Intrapericardial Empagliflozin-Loaded Exosome Hydrogel for Metabolic Reprogramming After Myocardial Infarction
By Lai Y, Guo Y, Zhuang X et al.
Background: Myocardial infarction remains a major antecedent of heart failure, and therapies that actively enhance infarct-zone repair, preserve viable myocardium, and limit adverse ventricular remodeling remain limited. Although empagliflozin has shown cardiometabolic benefits, systemic administration may not achieve sufficient local myocardial exposure during the early reparative window after infarction. A sustained intrapericardial delivery strategy may therefore amplify the reparative potential of empagliflozin by reprogramming the post-infarction microenvironment. Hypothesis: We tested whether intrapericardial delivery of an empagliflozin-loaded exosome hydrogel (Exo-Empa@HAMA) improves post-infarction myocardial repair by sustaining local drug exposure and reprogramming glycolytic metabolism within the infarct and peri-infarct regions. Methods: A phenylboronic acid-modified hyaluronic acid hydrogel loaded with empagliflozin-containing bone marrow mesenchymal stromal cell-derived exosomes (Exo-Empa@HAMA) was intrapericardially injected in a mouse myocardial infarction model. Cardiac function, survival, infarct expansion, ventricular remodeling, fibrosis, peri-infarct neovascularization, and inflammatory remodeling were assessed at days 7 and 28. Transcriptomics, metabolomics, Seahorse metabolic flux analysis, YAP localization and lactylation assays, and glycolysis-inhibition experiments were used to define the underlying repair mechanism. Results: Exo-Empa@HAMA formed a sustained intrapericardial depot with prolonged myocardial retention and controlled empagliflozin release. Compared with oral empagliflozin and Exo@HAMA, it improved 28-day survival, preserved left ventricular ejection fraction, reduced infarct expansion, remodeling, and fibrosis, and increased peri-infarct neovascularization. Multi-omics and metabolic flux analyses showed that Exo-Empa@HAMA restored glycolysis (increased ECAR and lactate). Mechanistically, Exo-Empa@HAMA promoted YAP stabilization, nuclear translocation and lactylation. Pharmacologic inhibition of glycolysis abolished lactate accumulation, suppressed YAP activation, and attenuated the functional, angiogenic, and anti-fibrotic benefits of Exo-Empa@HAMA, supporting glycolysis-dependent YAP activation as a necessary mechanism of post-infarction repair. Conclusion: Intrapericardial Exo-Empa@HAMA established a local metabolic delivery platform that enhanced myocardial repair, preserved cardiac function, and limited adverse remodeling after myocardial infarction in mice. By coupling sustained myocardial empagliflozin exposure to glycolysis-lactate-dependent YAP activation, this strategy provided a translational framework for reparative metabolic therapy after myocardial infarction.